Antiviral Lipid Nanocarrier Loaded with Remdesivir Effective Against SARS-CoV-2 in vitro Model

  • Int J Nanomedicine. 2023 Mar 27:18:1561-1575. doi: 10.2147/IJN.S391462.
Woo-Jin Jeon  #  1 ,  Hong-Ki Lee  #  2  3 ,  Young-Guk Na  1 ,  Minwoo Jung  1 ,  Su-Cheol Han  2 ,  Jeong Ho Hwang  2 ,  Eunhye Jung  4 ,  Dasom Hwang  4 ,  Jin Soo Shin  4 ,  Cheong-Weon Cho  1
Affiliations
  • 1. College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon, 34134, Republic of Korea.
  • 2. Center for Companion Animal New Drug Development, Jeonbuk Branch, Korea Institute of Toxicology (KIT), Jeongeup, Jeollabuk-do, 53212, Republic of Korea.
  • 3. Human Health Risk Assessment Center, Jeonbuk Branch, Korea Institute of Toxicology (KIT), Jeongeup, Jeollabuk-do, 53212, Republic of Korea.
  • 4. Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
  • # Contributed equally.
PMID: 37007987 DOI: 10.2147/IJN.S391462
Abstract

Introduction: The ongoing SARS-CoV-2 pandemic has affected public health, the economy, and society. This study reported a nanotechnology-based strategy to enhance the Antiviral efficacy of the Antiviral agent remdesivir (RDS).

Results: We developed a nanosized spherical RDS-NLC in which the RDS was encapsulated in an amorphous form. The RDS-NLC significantly potentiated the Antiviral efficacy of RDS against SARS-CoV-2 and its variants (alpha, beta, and delta). Our study revealed that NLC technology improved the Antiviral effect of RDS against SARS-CoV-2 by enhancing the cellular uptake of RDS and reducing SARS-CoV-2 entry in cells. These improvements resulted in a 211% increase in the bioavailability of RDS.

Conclusion: Thus, the application of NLC against SARS-CoV-2 may be a beneficial strategy to improve the Antiviral effects of Antiviral agents.

Keywords
SARS-CoV-2; antiviral effect; nanostructured lipid carrier; remdesivir; virus entry.
Products